Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsPanoulas, Vasileios F.
Douglas, Karen M. J.
Milionis, Haralampos J.
Metsios, Giorgos S.
Kita, Marina D.
Elisaf, Moses S.
Kitas, George D.
MetadataShow full item record
AbstractOBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors. Hypertension (HT), one of the most common risk factors for cardiovascular disease, is highly prevalent in RA. The effects of long-term glucocorticoid (GC) therapy on blood pressure have not been established yet. This study examined whether GC exposure associates with HT in patients with RA. METHODS: Four hundred consecutive RA patients with detailed clinical and laboratory assessments were categorized into three groups according to GC exposure: no or limited exposure (N/L-E); a low-dose (< 7.5 mg) long-term exposure (LD/LT-E); and medium-dose (> or = 7.5 mg) long-term exposure (MD/LT-E). The association of GC exposure with HT was evaluated using logistic regression analysis. RESULTS: HT was more prevalent in the MD/LT-E group (84.7%) than the LD/LT-E or N/L-E groups (70.7 and 67.3%, respectively, P = 0.028). Logistic regression revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01). CONCLUSIONS: MD/LT GC exposure associates with a very high prevalence of HT. This appears to be independent of other risk factors for HT or of channelling bias due to disease severity, even though the latter cannot be excluded given the cross-sectional nature of our study. RA patients in this GC exposure group should be particularly targeted for early identification and aggressive management of HT.
CitationRheumatology, 47(1): 72-75
PublisherOxford University Press
CollectionsSport, Exercise and Health Research Group
- Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.
- Authors: Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD
- Issue date: 2008
- Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.
- Authors: Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD
- Issue date: 2007 Sep
- Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study.
- Authors: Movahedi M, Costello R, Lunt M, Pye SR, Sergeant JC, Dixon WG
- Issue date: 2016 Oct
- Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis.
- Authors: Panoulas VF, Douglas KM, Milionis HJ, Nightingale P, Kita MD, Klocke R, Metsios GS, Stavropoulos-Kalinoglou A, Elisaf MS, Kitas GD
- Issue date: 2008 Mar
- Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?
- Authors: Morović-Vergles J, Salamon L, Marasović-Krstulović D, Kehler T, Sakić D, Badovinac O, Vlak T, Novak S, Stiglić-Rogoznica N, Hanih M, Bedeković D, Grazio S, Kadojić M, Milas-Ahić J, Prus V, Stamenković D, Sošo D, Anić B, Babić-Naglić D, Gamulin S
- Issue date: 2013 May